ADA: Efpeglenatide Lowers Risk for Adverse CV Events in T2DM
Findings among patients with type 2 diabetes and history of cardiovascular disease or current kidney disease
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.